Raytelligence offers products and services for non-contact monitoring vital signs of humans, that is respiration, heartbeat and motion patterns based on the company’s own 60 GHz radar technology.
Raised capital, in total SEK 26.3 million, will be used to position Raytelligence as a leading provider of non-contact measurement of vital parameters internationally.
Augment acted as financial advisor to Raytelligence in connection with the transaction.